Lewy Body Dementia

References

• Okazaki H, Lipkin L E, Aronson S M. Diffuse intracyto-plasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961; 20: 237–44
   PubMedGoogle Scholar
• Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990; 40: 1–8
   PubMed Web of Science ®Google Scholar
• Perry R H, Irving D, Blessed G, Fairbairn A, Perry E K. Senile dementia of Lewy body type: a clinically and neuropatho-logically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119–39
   PubMed Web of Science ®Google Scholar
• Perry R H, Irving D, Blessed G, Perry E K, Fairbairn A F. Clinically and pathologically distinct form of dementia in the elderly. Lancet 1989; i: 166
   Google Scholar
• Lewy F H. Paralysis agitans. Hand-buch der Neurologie, M Lawandowsky. Springer-Verlag, Berlin 1912; 920–58
   Google Scholar
• Tretiakoff C. Contribution a l'etude de l'anatomie patho-logique du locus niger de Soemmering avec quelques deductions relatives a la pathologie des troubles du tonus muscularie et de la maladie de Parkinson. University of Paris, Paris 1919
   Google Scholar
• Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree- a new disease?. Clin Neuropathol 1984; 3: 185–92
   PubMed Web of Science ®Google Scholar
• Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990; 237: 197–204
   PubMed Web of Science ®Google Scholar
• Yoshimura M. Cortical changes in the parkinsonian brain: a contribution to the delineation of ‘diffuse Lewy body disease’. J Neurol 1983; 229: 17–32
   PubMed Web of Science ®Google Scholar
• Hughes A J, Daniel S E, Blankson S, Lees A J. A clinico-pathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140–8
   PubMed Web of Science ®Google Scholar
• Brown D F, Dababo M A, Bigio E H, Risser R C, Eagan K P, Hladik C L, et al. Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson disease. J Neuropathol Exp Neurol 1998; 57: 39–46
   PubMed Web of Science ®Google Scholar
• Hansen L A, Masliah E, Galasko D, Terry R D. Plaque-only Alzheimer disease is usually the Lewy body variant, and vice versa. J Neuropathol Exp Neurol 1993; 52: 648–54
   PubMed Web of Science ®Google Scholar
• Lippa C F, Smith T W, Swearer J M. Alzheimer's disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 1994; 35: 81–8
   PubMed Web of Science ®Google Scholar
• Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer's disease clinical and pathological findings. Br J Psychiatry 1993; 162: 385–92
   PubMed Web of Science ®Google Scholar
• McKeith I G, Galasko D, Kosaka K, Perry E K, Dickson D W, Hansen L A, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–24
   PubMed Web of Science ®Google Scholar
• Weiner M F, Risser R C, Cullum C M, Honig L, White C, III, Speciale S, et al. Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry 1996; 153: 1269–73
   PubMedGoogle Scholar
• Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang M-X, Cote L J, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49: 492–7
   PubMed Web of Science ®Google Scholar
• Burkhardt C R, Filley C M, Kleinschmidt-DeMasters B K, de la Monte S, Norenberg M D, Schneck S A. Diffuse Lewy body disease and progressive dementia. Neurology 1988; 38: 1520–8
   PubMed Web of Science ®Google Scholar
• Byrne E J, Lennox G, Louin J, Godwin-Austen R B. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989; 52: 709–17
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Yoshimura M. Clinical and neuropathologic aspects of diffuse Lewy body disease. Adv Neurol 1993; 60: 464–9
   PubMedGoogle Scholar
• Olichney J M, Galasko D, Salmon D P, Hofstetter C R, Hansen L A, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998; 51: 351–7
   PubMed Web of Science ®Google Scholar
• McKeith I G, Perry R H, Fairbairn A F, Jabeen S, Perry E K. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992; 22: 911–22
   PubMed Web of Science ®Google Scholar
• Salmon D P, Galasko D, Hansen L A, Masliah E, Butters N, Thai L, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn 1996; 31: 148–65
   PubMed Web of Science ®Google Scholar
• Graham C, Ballard C, Saad K. Variables which distinguish patients fulfilling clinical criteria for dementia with Lewy bodies from those with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 314–8
   PubMedGoogle Scholar
• Connor D J, Salmon D P, Sandy T J, Galasko D, Hansen L A, Thai L. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998; 55: 994–1000
   PubMed Web of Science ®Google Scholar
• Salmon D P, Galasko D. Neuropsychological aspects of Lewy body dementia. Lewy Body Dementia, E K Perry, R H Perry, I McKeith. Cambridge University Press, New York 1996; 99–113
   Google Scholar
• Gibb W, Esiri M, Lees A. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987; 110: 1131–53
   PubMedGoogle Scholar
• Cummings J L. The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Eur Neurol 1988; 28: 15–23
   PubMed Web of Science ®Google Scholar
• Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990; 40: 1513–7
   PubMed Web of Science ®Google Scholar
• Yoshimura M. Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease. Eur Neurol 1988; 28: 29–35
   Google Scholar
• Galasko D, Katzman R, Salmon D P, Hansen L. Clinical and neuropathological findings in Lewy body dementias. Brain Cogn 1996; 31: 166–75
   PubMed Web of Science ®Google Scholar
• Louis E D, Klatka L A, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997; 48: 376–80
   PubMed Web of Science ®Google Scholar
• McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673–8
   PubMed Web of Science ®Google Scholar
• McKeith I G, Fairbairn A F, Bothwell R A, Moore P B, Ferrier I N, Thompson P, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994; 44: 872–7
   PubMed Web of Science ®Google Scholar
• Crystal H A, Dickson D W, Lizardi J E, Davies P, Wolfson L I. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990; 40: 1523–8
   PubMedGoogle Scholar
• Klatka L A, Louis E D, Schiffer R B. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996; 47: 1148–52
   PubMed Web of Science ®Google Scholar
• Litvan I, Maclntyre A, Goetz C G, Wenning G K, Jellinger K, Verny M, et al. Accuracy of the clinical diagnosis of Lewy body disease, Parkinson disease, and dementia with Lewy bodies; a clinicopathologic study. Arch Neurol 1998; 55: 969–78
   PubMed Web of Science ®Google Scholar
• Byrne E J, Lennox G, Godwin-Austen R B. Dementia associated with cortical Lewy bodies: proposed clinical diagnostic criteria. Dementia 1991; 2: 283–4
   Google Scholar
• Kosaka K. Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol 1978; 42: 127–34
   Google Scholar
• Kosaka K, Oyanagi S, Matsushita M, Hori A, Iwase S. Presenile dementia with Alzheimer-, Pick-, and Lewy body changes. Acta Neuropathol 1976; 36: 221–33
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hori A, Boda G. Progressive dementia with ‘diffuse Lewy-type inclusion’ in cerebral cortex. Arch Psychiatr Nervenkr 1980; 228: 243–248
   Google Scholar
• Forno L S. The Lewy body in Parkinson's disease. Adv Neurol 1986; 45: 35–43
   Google Scholar
• Kosaka K, Matsushita M, Oyanagi S, Mehraein P. A clinicopathological study of the “Lewy body disease”. Psychiatr Neurol Jap 1980; 82: 292–311
   Google Scholar
• Lennox G, Lowe J, Morrell K, Landon M, Mayer R J. Anti-ubiquitin immunohistochemistry is more sensitive than conventional techniques in detecting diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989; 52: 67–71
   PubMed Web of Science ®Google Scholar
• Irizarry M C, Growdon W, Gomez-Isla T, Newell K, George J M, Clayton D F, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immuno-reactivity. J Neuropathol Exp Neurol 1998; 57: 334–7
   PubMedGoogle Scholar
• Baba M, Nakajo S, Tu P, Tomita T, Nakaya K, Lee V MY, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am j Pathol 1998; 152: 879–84
   PubMed Web of Science ®Google Scholar
• Galloway P G, Grundke-Iqbal I, Iqbal K, Perry G. Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles. J Neuropathol Exp Neurol 1988; 47: 654–63
   PubMed Web of Science ®Google Scholar
• Goldman J, Yna S, Chiu F, Peress N. Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 1983; 221: 1082–4
   PubMed Web of Science ®Google Scholar
• Forno L S, Sternberger L A, Sternberger N H, Strefling A M, Swanson K, Eng L F. Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. Neurosci Lett 1986; 64: 253–8
   Google Scholar
• Pappolla M A. Lewy bodies of Parkinson's disease. Immune electron microscopic demonstration of neurofilament antigens in constituent filaments. Arch Pathol Lab Med 1986; 110: 1160–3
   Google Scholar
• Nishimura M, Tomimoto H, Suenaga T, Nakamura S, Namba Y, Ikeda K, et al. Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in Parkinson's disease brain. Brain Res 1994; 634: 339–44
   Google Scholar
• Spillantini M G, Schmidt M L, Lee V M, Trojanowski J Q, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40
   PubMed Web of Science ®Google Scholar
• Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, Ihara Y. Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol 1988; 75: 345–53
   PubMed Web of Science ®Google Scholar
• Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease as well as Rosenthal fibers in cerebellar astrocytomas, cytoplasmic bodies in muscle and Mallory's bodies in alcoholic liver disease. J Pathol 1988; 155: 9–15
   PubMed Web of Science ®Google Scholar
• Dickson D W, Ruan D, Crystal H, Mark M H, Davies P, Kress Y, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2–3 neurites specific to DLBD. Neurology 1991; 41: 1402–9
   PubMed Web of Science ®Google Scholar
• McKenzie J E, Edwards R J, Gentleman S M, Ince P G, Perry R H, Royston M C, et al. A quantitative comparison of plaque types in Alzheimer's disease and senile dementia of the Lewy body type. Acta Neuropathol 1996; 91: 526–9
   PubMedGoogle Scholar
• Harrington C R, Perry R H, Perry E K, Hurt J, McKeith I G, Roth M, et al. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 1994; 5: 215–28
   PubMedGoogle Scholar
• Mirra S S, Hart M N, Terry R D. Making the diagnosis of Alzheimer's disease: a primer for practicing pathologists. Arch Pathol Lab Med 1993; 117: 132–44
   PubMed Web of Science ®Google Scholar
• Hulette C, Mirra S, Wilkinson W, Heyman A, Fillenbaum G, Clark C. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IX. A prospective clinico-neuropathologic study of Parkinson's features in Alzheimer's disease. Neurology 1995; 45: 1991–5
   Google Scholar
• White C LHI, Tripp P, Eagan K P, Welch E, Stiegler A, Bigio E H. Quantification of synapse density in Alzheimer disease neocortex using a two-site enzyme-linked immunosorbant assay (ELISA) and antibodies to synaptophysin. J Neuropathol Exp Neurol 1995; 54: 430
   Google Scholar
• Terry R D, Masliah E, Salmon D P, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572–80
   PubMed Web of Science ®Google Scholar
• DeKosky S T, Scheff S W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457–64
   PubMed Web of Science ®Google Scholar
• McKee A C, Kosik K S, Kowall N W. Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 1991; 30: 156–65
   PubMed Web of Science ®Google Scholar
• Arriagada P V, Growdon J H, Hedley-Whyte E T, Hyman B T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992; 42: 631–9
   PubMed Web of Science ®Google Scholar
• Bierer L M, Hof P R, Purohit D P, Carlin L, Schmeidler J, Davis K L, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995; 52: 81–8
   PubMedGoogle Scholar
• Berg L, McKeel D, Miller J P, Baty J, Morris J C. Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 1993; 50: 349–58
   PubMedGoogle Scholar
• Samuel W, Galasko D, Masliah E, Hansen L A. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 44–52
   Google Scholar
• Brown D F, Risser R C, Bigio E H, Tripp P, Stiegler A, Welch E, et al. Neocortical synapse density and Braak stage in Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol 1998; 57: 955–60
   Google Scholar
• Samuel W, Alford M, Hofstetter C R, Hansen L. Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density. J Neuropathol Exp Neurol 1997; 56: 499–508
   PubMedGoogle Scholar
• Lennox G, Lowe J, Landon M, Byrne E J, Mayer R J, Godwin-Austen R B. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989; 52: 1236–17
   PubMed Web of Science ®Google Scholar
• Perry E K, Irving D, Kerwin J M, McKeith I G, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7: 69–79
   PubMed Web of Science ®Google Scholar
• Langlais P J, Thai L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993; 43: 1927–34
   PubMedGoogle Scholar
• Lloyd K G. CNS compensation to dopamine neuron loss in Parkinson's disease. Adv Exp Med Bio 1977; 90: 255–6
   PubMedGoogle Scholar
• Polymeropoulos M H, Lavedan C, Leroy E, Ide S E, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–7
   PubMed Web of Science ®Google Scholar
• Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106–8
   PubMed Web of Science ®Google Scholar
• Denson M A, Wszolek Z K, Pfeiffer R F, Wszolek E K, Paschall T M, McComb R D. Familial parkinsonism, dementia, and Lewy body disease: study of family G. Ann Neurol 1997; 42: 638–43
   Google Scholar
• Ishikawa A, Takahashi H, Tanaka H, Hayashi T, Tsuji S. Clinical features of familial diffuse Lewy body disease. Eur Neurol 1997; 38: 34–8, Suppl 1
   Google Scholar
• El-Agnaf O M, Curran M D, Wallace A, Middleton D, Murgatroyd C, Curtis A, et al. Mutation screening in exons 3 and 4 of alpha-synuclein in sporadic Parkinson's and sporadic and familial dementia with Lewy bodies. Neuro-report 1998; 9: 3925–7
   Google Scholar
• Munoz E, Olivia R, Obach V, Marti M J, Pastor P, Ballesta F, et al. Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients. Neurosci Lett 1997; 235: 57–60
   Google Scholar
• Farrer M, Wavrant-De Vrieze F, Crook R, Boles L, Perez-Tur J, Hardy J, et al. Low frequency of alpha-synuclein mutations in familial Parkinson's disease. Ann Neurol 1998; 43: 394–7
   Google Scholar
• Wang W W, Khajavi M, Patel B J, Beach J, Jankovic J, Ashizawa T. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol 1998; 55: 1521–3
   Google Scholar
• Vaughan J, Durr A, Tassin J, Bereznai B, Gasser T, Bonifati V, et al. The alpha-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: a study of 230 European cases. European Consortium on Genetic Susceptibility in Parkinson's Disease. Ann Neurol 1998; 44: 270–3
   PubMed Web of Science ®Google Scholar
• Chan P, Tanner C M, Jiang X, Langston J W. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998; 50: 513–4
   PubMed Web of Science ®Google Scholar
• Warner T T, Schapira A H. The role of the alpha-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom. J Neurol Neurosurg Psychiatry 1998; 65: 378–9
   Google Scholar
• Tu P H, Galvin J E, Baba M, Giasson B, Tomita T, Leight S, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998; 44: 415–22
   PubMed Web of Science ®Google Scholar
• Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 11282–6
   PubMed Web of Science ®Google Scholar
• Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol 1996; 148: 201-–10
   PubMedGoogle Scholar
• Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, Rohan de Silva H A, et al. The precursor protein of non-Ab component of Alzheimer's disease is a presynaptic protein of the central nervous system. Neuron 1995; 14: 467–75
   PubMed Web of Science ®Google Scholar
• Forstl H, Burns A, Levy R, Cairns N, Luthert P, Lantos P. Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease. Br J Psychiatry 1993; 163: 364–8
   Google Scholar
• Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994; 343: 176
   PubMed Web of Science ®Google Scholar
• Lebert F, Pasquier F, Souliez L, Petit H. Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998; 13: 516–9
   PubMed Web of Science ®Google Scholar
• Liberini P, Valerio A, Memo M, Spano P F. Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?. Trends Pharmacol Sci 1996; 17: 155–60
   PubMedGoogle Scholar
• Allen R L, Walker Z, D'Ath P J, Katona C L. Risperidone for psychotic and behavioral symptoms in Lewy body dementia. Lancet 1995; 346: 185
   PubMed Web of Science ®Google Scholar
• Geroldi C, Frisoni G B, Bianchetti A, Trabucchi M. Drug treatment in Lewy body dementia. Dement Geriatr Cogn Disord 1997; 8: 188–97
   PubMed Web of Science ®Google Scholar
• Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with odansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305–8
   PubMed Web of Science ®Google Scholar
• Kaufer D L, Catt K E, Lopez O L, DeKosky S T. Dementia with Lewy bodies: response of delirium-like features to donezepil. Neurology 1998; 51: 1512
   PubMed Web of Science ®Google Scholar
• McKeith I G, Ballard C G, Harrison R WS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346: 699
   PubMed Web of Science ®Google Scholar
• Burke W J, Pfeiffer R F, McComb R D. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998; 10: 227–9
   PubMed Web of Science ®Google Scholar